Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Zorubicin"'
Autor:
Xiaoxun Yang, Ling-Bo Qu, Ji-Chao Wang, Deng Shaoxin, Cheng-Xing Cui, Linfeng Hu, Duan Lingyao, Yu-Ping Zhang
Publikováno v:
ACS Omega, Vol 6, Iss 1, Pp 553-558 (2020)
ACS Omega
ACS Omega
Targeted release of anticancer drugs to tumor sites has a pivotal role in clinical oncology. pH-responsive drug delivery systems, with an intelligent and targeted release of anticancer drugs in a controllable manner based on sensitivities to the weak
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08b382c0897483dd3dadf8eaf26ad5c5
https://doaj.org/article/2fafe672cbb74b389ffd5e172a496e47
https://doaj.org/article/2fafe672cbb74b389ffd5e172a496e47
Autor:
Lieve Vandenbossche-simon, Pierre Fenaux, Brigitte Nelken, Francis Bauters, J. P. Pollet, Marc Zandecki
Publikováno v:
Leukemialymphoma. 2(6)
We report 11 children (aged less than 20 years) with acute promyelocytic leukemia (APL), who represented 14% of our total number of patients with APL. There were 8 girls and 3 boys and the median age was 13.5 (range 3-19). Extramedullary leukemia was
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ceb0feec55fe1f410b5a2280c468fa16
https://pubmed.ncbi.nlm.nih.gov/27457044
https://pubmed.ncbi.nlm.nih.gov/27457044
Publikováno v:
Scandinavian Journal of Haematology. 32:385-390
Between 1978 and 1980, 45 cases of acute monoblastic leukaemia have been diagnosed, treated and followed in our institute. Morphological diagnosis was performed according to the French-American-British classification. Tumoral syndrome (particularly e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6898e7ede8248a8cfd4766ae74e87af4
https://doi.org/10.1111/j.1600-0609.1984.tb00693.x
https://doi.org/10.1111/j.1600-0609.1984.tb00693.x
Publikováno v:
The Cochrane Library
Background Anthracycline combined with cytarabine has been the standard for induction therapy of newly diagnosed acute myeloid leukaemia (AML) for several decades. Due to theoretical advantages, idarubicin (IDA) might be the most effective and tolera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f914a5b8bf765035a526755821b2957f
https://doi.org/10.1002/14651858.cd010432.pub2
https://doi.org/10.1002/14651858.cd010432.pub2
Publikováno v:
Acta chirurgica Iugoslavica. 51:61-67
Indifferentiated carcinoma of the nasopharyngs is clinicaly-histological-imunologic entity which is often diagnosed in our country .There are three clinical types, but nodal cervical type of disease is the most interesting type for surgeons while the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b75a89b6100f1dd0c812e17bdda5cc41
https://doi.org/10.2298/aci0401061s
https://doi.org/10.2298/aci0401061s
Publikováno v:
Tumori Journal. 84:677-680
Background and aims Second-line chemotherapy regimens for advanced soft tissue sarcomas after treatment failure or tumor relapse following anthracyclines are still investigational. The aim of the present study was to assess the activity of ifosfamide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c2f98e8f4531900ffbcfde6c417a9d2
https://doi.org/10.1177/030089169808400613
https://doi.org/10.1177/030089169808400613
Autor:
M Stagg, Franco Mandelli, Matthew Clarke, M. Mercier, R Alison, Françoise Huguet, Jean-Jacques Sotto, Z Tellier, Peter H. Wiernik, C Hicks, Keith Wheatley, A Tooth, Grp Amlc., V Evans, Richard Gray, Josy Reiffers, E Greaves, William R. Vogler, S James, D Wheatley, Susan M. Richards, Richard Peto, Emma Hall, V Polin, J P Dutcher, A. M. Stoppa, W R Bezwoda, M C Petti, Jean Luc Harousseau, E Berman, DA Sinclair
Publikováno v:
British Journal of Haematology. 103:100-109
A collaborative overview, using individual patient data, has been performed to compare idarubicin versus daunorubicin or other anthracyclines, when used with cytosine arabinoside as induction chemotherapy for newly diagnosed acute myeloid leukaemia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62197586116c7f7f5e274fa17ab1eba2
https://doi.org/10.1046/j.1365-2141.1998.00948.x
https://doi.org/10.1046/j.1365-2141.1998.00948.x
Autor:
R Leblay, Guy H, E Le Gall, Guy Leverger, Dominique Bordessoule, Philippe Colombat, Sylvie Castaigne, Pierre Fenaux, Hervé Tilly, G Tertian
Publikováno v:
Journal of Clinical Oncology. 9:1556-1561
Thirty-nine patients with untreated acute promyelocytic leukemia (APL) were randomly allocated to receive rubidazone (zorubicin) 200 mg/m2/d, days 1 to 4 plus cytarabine (Ara C) 200 mg/m2/d, days 1 to 7 (arm A, 21 patients), or amsacrine (Amsa) 150 m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d9670d0597baed2ec8b0fb3d903e96e
https://doi.org/10.1200/jco.1991.9.9.1556
https://doi.org/10.1200/jco.1991.9.9.1556
Autor:
Pascale Lepelley, Jean Luc Laï, Stéphane de Botton, Eric Wattel, Francis Bauters, Pierre Fenaux, Claude Preudhomme
Publikováno v:
British journal of haematology. 98(4)
The percentage of long-term survivors after intensive chemotherapy and the outcome of MDS patients who achieve partial remission (PR) with intensive chemotherapy (IC) are not known. Between 1981 and 1996 we treated 99 patients with de novo MDS who ha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9dd8d8bd3aa1898ce07571e905bd7bdb
https://pubmed.ncbi.nlm.nih.gov/9326199
https://pubmed.ncbi.nlm.nih.gov/9326199
Autor:
I. Pendjer, Svetislav Jelić, V. Jovanovic, L. Mitrović, N. Milanović, Miroslav Kreačić, V. Kovčin, M. Opric, Z. Ristović
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 8(8)
Summary Background: The most active chemotherapy regimens in UCNT were those combining anthracyclines (doxorubicin or epirubicin) and cisplatin. Our previous pilot study on 37 patients treated with the zorubicin-cisplatin combination with a RR of 67%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a10f470a4c008f09d99e9733fa507d8f
https://pubmed.ncbi.nlm.nih.gov/9332678
https://pubmed.ncbi.nlm.nih.gov/9332678